Greg Henkel - Concepedia

Author

Greg Henkel

Arisan Therapeutics (United States)ORCID

Also Known As

G Henkel, Greg Henkel, Greg W Henkel

Publications

659

Citations

H-Index

Concepts

All Affiliations

Arisan Therapeutics (United States)Oregon Health & Science University Vertex Pharmaceuticals (United States)University of California San Diego Novartis (United States)

About

Greg Henkel is an author at Arisan Therapeutics (United States) specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	249
2	Cell Biology	4	4	235
3	Allergy	2	2	198
4	Health Sciences	1	1	20
5	Biomolecular Engineering	1	1	14

Greg Henkel

Publications

648

Citations

H-Index

Page 1

	Year	Citations
IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients Jeffrey H. Stack, Kevin Beaumont, Paul D. Larsen, The Journal of Immunology	2005	187
PU.1 and GATA: components of a mast cell-specific interleukin 4 intronic enhancer. Greg Henkel, Matthew A. Brown Proceedings of the National Academy of Sciences Murine Il-4 GeneMast Cell DisorderImmunologyImmune RegulationImmune System	1994	122
An Intron Transcriptional Enhancer Element Regulates IL-4 Gene Locus Accessibility in Mast Cells John Hural, Millie Kwan, Greg Henkel, The Journal of Immunology	2000	79
A DNase I-hypersensitive site in the second intron of the murine IL-4 gene defines a mast cell-specific enhancer Greg Henkel, D L Weiss, R. J. McCoy, The Journal of Immunology	1992	78
Nuclear Factor of Activated T Cells Is Associated with a Mast Cell Interleukin 4 Transcription Complex D L Weiss, John Hural, David Tara, Molecular and Cellular Biology Mast Cell DisorderT-regulatory CellImmunologyImmune RegulationInflammation	1996	76
Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors Michael Plewe, Vidyasagar Reddy Gantla, Eric Brown, ACS Medicinal Chemistry Letters	2020	22
Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia Robert J.O. Davies, Albert C. Pierce, Cornelia J. Forster, Journal of Medicinal Chemistry Excellent PotencyMixed-phenotype Acute LeukemiaAcute Myelogenous LeukemiaMyeloid NeoplasiaHematological Malignancy	2011	20
VX-322: A Novel Dual Receptor Tyrosine Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia David K. Heidary, George Q. Huang, Diane M. Boucher, Journal of Medicinal Chemistry Hematological MalignancyNovel TherapyMedicineMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2012	17
Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors Michael Plewe, Vidyasagar Reddy Gantla, Young-Jun Shin, Bioorganic & Medicinal Chemistry Letters MedicineAntiviral Drug DevelopmentAntiviral TherapyVirologyAntiviral Drug	2021	14
Potent inhibition of arenavirus infection by a novel fusion inhibitor Brian B. Gowen, Shibani Naik, Jonna B. Westover, Antiviral Research	2021	12

Page 1